MIAMI, Sept. 10, 2012 /PRNewswire/ -- Nuovo Biologics, LLC announced that Robert G. Savage has joined its Board. Mr. Savage served as Group Vice President and President General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003. From 1996 through 2001, Mr. Savage served Johnson & Johnson in a variety of roles, most recently as Worldwide Chairman of Johnson and Johnson’s Pharmaceutical Group. From 1985 to 1996 he served Roche Holding AG in a variety of senior marketing, business development and operations positions, most recently as Vice President Marketing, Hoffman-La Roche, Inc. He is currently a director of EpiCept Corporation and The Medicines Company. Mr. Savage was a member of the Board of Directors of Noven Pharmaceuticals, Inc. from 2004 until 2009 when the company was sold to Hisamitsu Pharmaceuticals Company. Mr. Savage has been the President of Strategic Imagery LLC, a pharmaceutical consultancy, since 2003.
Donald A. Denkhaus, Chairman of the Board of Nuovo Biologics stated, “We are exceptionally fortunate to have a pharmaceutical executive with such a wealth of experience join our Board. Bob’s leadership, strategic vision and marketing experience will help move our company to the next level.”
Dr. Jay Yourist, CEO said, “Nuovo’s first drug in the U.S. will be a broad spectrum antiviral to treat companion animals. Ultimately, approval for human uses for our drugs will be sought. We are particularly pleased that Bob is joining our Board, especially in light of his past responsibility of developing and launching several antiviral and anti-bacterial drugs including Rocephin (ceftriaxone) and Tamiflu (oseltamivir) while he was at Roche and Levaquin (levofloxacin) while he was at Johnson & Johnson.” Tamiflu is currently a leading antiviral drug with billions in sales globally since its launch.
Nuovo Biologics, LLC is a Florida based biopharmaceutical company that is pursing innovative health products and technologies.
SOURCE Nuovo Biologics, LLC
